{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:49:52Z","timestamp":1767178192869,"version":"build-2238731810"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0108048","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T13:53:25Z","timestamp":1413294805000},"page":"e108048","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00369070","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00460317","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael B.","family":"Bass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jiang","family":"Hei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yining","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Kaesdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"P Carmeliet","year":"2011","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.2174\/138161212800626166","article-title":"Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer","volume":"18","author":"G Korpanty","year":"2012","journal-title":"Curr Pharm Des"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2174\/156800911795655985","article-title":"VEGF\/VEGFR pathway inhibitors as anti-angiogenic agents: present and future","volume":"11","author":"PS Sharma","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s10637-011-9750-1","article-title":"Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC)","volume":"30","author":"GR Blumenschein Jr","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref5","article-title":"Markers of response for the antiangiogenic agent bevacizumab","author":"D Lambrechts","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/JTO.0000000000000160","article-title":"A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)","volume":"9","author":"T Mok","year":"2014","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts","volume":"66","author":"A Polverino","year":"2006","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","article-title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors","volume":"25","author":"LS Rosen","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"MJ Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"SI Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdq731","article-title":"A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer","volume":"22","author":"GR Blumenschein Jr","year":"2011","journal-title":"Ann Oncol"},{"key":"ref12","first-page":"2696","article-title":"Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1","volume":"61","author":"CJ Green","year":"2001","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1172\/JCI119069","article-title":"In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor\/vascular endothelial growth factor","volume":"98","author":"Y Cao","year":"1996","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"P Carmeliet","year":"2001","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nm731","article-title":"Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1","volume":"8","author":"A Luttun","year":"2002","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1538-7836.2003.00263.x","article-title":"Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders","volume":"1","author":"M Autiero","year":"2003","journal-title":"J Thromb Haemost"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-3-68","article-title":"Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance","volume":"3","author":"L Zhang","year":"2005","journal-title":"World J Surg Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/jco.2010.28.15_suppl.3037","article-title":"Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non\u2013small-cell lung cancer, and locally recurrent or advanced metastatic breast cancer [abstract]","volume":"28","author":"MB Bass","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/jco.2010.28.15_suppl.1048","article-title":"Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (Pts) with locally recurrent or advanced metastatic breast cancer [abstract\/poster]","volume":"28","author":"SD Patterson","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1210\/jc.2010-0947","article-title":"Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer","volume":"95","author":"MB Bass","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.2007.15.5416","article-title":"Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma","volume":"26","author":"BI Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-09-2533","article-title":"Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib","volume":"70","author":"PG Nikolinakos","year":"2010","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"CG Willett","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-10-2331","article-title":"Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib","volume":"17","author":"RJ Kelly","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"SE Deprimo","year":"2007","journal-title":"J Transl Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma","volume":"28","author":"TT Batchelor","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1200\/JCO.2011.41.4987","article-title":"International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1","volume":"30","author":"GV Scagliotti","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"P Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Russell CB, Suggs S, Robson KM, Kerkof K, Kivman LD, et al. (2008) Biomarker sample collection and handling in the clinical setting to support early phase drug development. In: Wang F, editor. Biomarker Methods in Drug Discovery and Development. Totowa, NJ: Humana Press. 1\u201326","DOI":"10.1007\/978-1-59745-463-6_1"},{"key":"ref30","unstructured":"Cox DR, Oakes D (1984) Analysis of Survival Data. Boca Raton, FL: Chapman & Hall\/CRC."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2307\/2529881","article-title":"Maximally selected chi square statistics","volume":"38","author":"R Miller","year":"1982","journal-title":"Biometrics"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"PJ Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"ref33","unstructured":"Kutner M, Nachtsheim C, Neter J, Li W (2005) Applied Linear Statistical Models. New York, NY: McGraw Hill\/Irwin. 1\u201326 p."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Y Benjamini","year":"1995","journal-title":"J Royal Statistical Soc B"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","article-title":"A concordance correlation coefficient to evaluate reproducibility","volume":"45","author":"LI Lin","year":"1989","journal-title":"Biometrics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1200\/JCO.2012.43.3946","article-title":"Randomized phase II trial designs with biomarkers","volume":"30","author":"B Freidlin","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pst.219","article-title":"Methodological issues with adaptation of clinical trial design","volume":"5","author":"HM Hung","year":"2006","journal-title":"Pharm Stat"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/00365513.2010.493361","article-title":"Development of novel IVD assays: a manufacturer's perspective","volume":"Suppl 242","author":"TA Metcalfe","year":"2010","journal-title":"Scand J Clin Lab Invest"},{"key":"ref39","first-page":"178sr173","article-title":"Statistical challenges in the evaluation of treatments for small patient populations","volume":"5","author":"EL Korn","year":"2013","journal-title":"Sci Transl Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1158\/0008-5472.CAN-12-3232","article-title":"Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures","volume":"72","author":"SE Kern","year":"2012","journal-title":"Cancer Res"},{"key":"ref41","unstructured":"US Food and Drug Administration (2010) Guidance for industry: qualification process for drug development tools (draft guidance). Rockville, MD."}],"updated-by":[{"DOI":"10.1371\/journal.pone.0121162","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0108048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T18:21:24Z","timestamp":1717438884000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0108048"}},"subtitle":[],"editor":[{"given":"Jose Luis","family":"Perez-Gracia","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0108048","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}